Study Details

Back
Study ID 905-CL-055
Study Title A randomized, double-blind, parallel group, placebo controlled,multi-center study of fixed dose combinations of solifenacin succinate(6 mg and 9 mg) with tamsulosin hydrochloride OCAS 0.4 mg andtamsulosin hydrochloride OCAS 0.4 mg monotherapy, in male subjectswith lower urinary tract symptoms (LUTS) associated withbenign prostatic hyperplasia (BPH) with a substantial storage component
Clinicaltrials.gov Identifier NCT01018511
Compound Name EC905 / solifenacin + tamsulosin
Medical Indication or Disease Lower urinary tract syndrome / Benign prostatic hyperplasia
Study Sponsor Astellas Pharma Europe B.V.
Collaborator Not Applicable
Study Start Date 11-Jan-2010
Study Completion Date 01-Mar-2011
Clinical Study Result
Select the language
English
Plain Language Summary
Select the language
English

QUICK SEARCH

USEFUL LINKS